QCLS missed EPS expectations by 130.60%
Sep 29, 2025, 10:33 AM
0.00%
What does QCLS do
MyMD Pharmaceuticals, based in Baltimore, develops drug products for aging, autoimmune diseases, and chronic pain, focusing on two platforms: MYMD-1 for inflammation and Supera-CBD for pain and addiction. The company went public in 2008 and employs nine people.
Q/C Technologies (QCLS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Q/C Technologies's actual EPS was -$230400.00, missing the estimate of $70502.40 per share, resulting in a -130.60% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.